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This thesis reports the crystallization of two new quasiracemates, the synthesis of
a new oxadiazinanone and the identification of crystals of two new compounds. In
previous research the quasiracemates, (5R,6S )-4-cyclohexyl-5-methyl-6-phenyl-2H1,3,4-oxadiazinan-2-one and (5S,6R)-4-isopropyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one, were mixed in solution and crystallized. Instead of fractionally
crystallizing, as would be expected, the compounds formed quasiracemic co-crystals.
This suggested that other mixtures of oxadiazinanones would be possible candidates for
studying compounds which fail to fractionally crystallize.
The first step in the process involves the synthesis of oxadiazinanones, using
literature methods. A 4-step process is employed involving alkylation, nitrosation,
reduction and cyclization. Because the starting material, norephedrine, is a chiral
molecule, the desired enantiomer is synthesized starting with the proper enantiomer of
norephedrine—either the (1S,2R) or 1(R,2S) enantiomers. A new oxadiazinanone,
(5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one, was synthesized.
After synthesis, the oxadiazinanones are mixed together and crystallized using vapor

diffusion. X-ray diffraction is used to study the structures to determine the presence of
quasiracemates.
From the sixteen racemic pairs compared, it was found that quasiracemates were
formed from oxadiazinanones containing either an N4-cyclopentyl substituent or an N4cyclohexyl substituent. The quasiracemate formed has a lower Z’ than at least one of the
quasienantiomers in the structure.
Two additional compounds were synthesized, and the crystal structures were
identified . These crystals were obtained when the intended N4-ethylated and N4-nbutylated oxadiazinanones failed to cyclize in the final step of the oxadiazinanone
synthesis.
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CHAPTER I
OXADIAZINANONE RESEARCH-HOW AND WHY?
Fractional Crystallization
Typically, when different compounds are mixed together and crystallized, the
components of the mixture crystallize as pure compounds. This happens at different times
based on the solubility of each of the compounds. This process, called fractional
crystallization, is used as a separation technique in industrial applications. In a solution,
the desired product is usually present in a greater concentration than the impurities and,
generally, is deposited first. The impurities are left in solution. The failure to fractionally
crystallize occurs when one of the compounds co-crystallizes with another compound
also present in the solution. This results in a new crystalline product which is a
combination of the original compounds.1
Several conditions seem to increase the likelihood of co-crystallization.
When enantiomers crystallize they almost always co-crystalize as the corresponding
racemate. This is due to the presence of symmetry elements, such as inversion or glide
planes, which are very favorable to crystal-packing as well as the fact that both
enantiomers have identical physical properties, including solubility. In fact, the
occurrence of fractional crystallization of enantiomers is so rare it is given a special
name, spontaneous resolution. When a crystal has inversion or glide planes as symmetry
elements, the crystal is able to pack more densely which decreases the size of the crystal.
1

This decrease in size and increase in density is favorable to crystal. packing.2
Quasiracemates, as defined by the International, Union of Pure and Applied Chemistry
(IUPAC), are crystals composed of a 1:1 ratio of “almost enantiomers.”3 Husebye, in the
1960s, reported that quasiracemates generally have structures with a great deal of
similarity to the corresponding racemates. This observation may provide some support to
the importance of inversion symmetry in co-crystallization.1, 4 Quasiracemates, because
they have pseudo inversion centers, may be able to pack in a smaller volume, thus
reducing the size of the asymmetric unit in the same manner as the co-crystallization
observed in racemates.
In addition to strong inversion symmetry, hydrogen-bonding contributes to cocrystallization.2 Hydrogen bonds are somewhat elastic and this elasticity allows the
distances and angles to vary at a small cost in energy which simplifies the bonding in a
co-crystal. Therefore, there are a large number of co-crystals with either a carboxylic
group or an amide group.1
Often, however, it is difficult to determine the reason for co-crystallization.
Kelley et al, created a list of quasiracemic crystals.1 The definition the researchers
employed stated that quasiracemic crystals are co-crystals formed by molecules which
are almost enantiomers but differ by the substitution of a few atoms. Of particular note is
that the researchers found the formation of quasiracemic crystals is rare. In 2011 there
were over 400,000 structures in the Cambridge Structural Database. Of these, only 114
quasiracemates were identified as quasiracemates.1

2

A Brief History of Quasienantiomer Research
Louis Pasteur’s earliest chemical studies were in the field of crystallography. In
1846, he found that tartaric acid had optical activity, but paratartaric acid had none
leading him to believe there were two kinds of crystals present although most other
chemical properties were the same in the two compounds. He noticed that the edges of
the crystals were asymmetrical—the surfaces on some of them were facing right and
some, left. Using a dissecting needle and a microscope, he separated the crystals into two
piles based on these differences. He recognized the difference in optical activity,
extended his observations to the molecular level and realized that the two kinds of
crystals were mirror images. He wrote his doctoral dissertation on this subject in 1847.5, 6
The basis for chirality and stereoisomerism was laid by van’t Hoff and Le Bel in
1874 when, independently, they each proposed the existence of tetrahedral carbon with a
tetrahedral valence. In consequence of this, the idea of enantiomerism came into being.
Enantiomers are compounds with the same chemical constitution which are mirrorimages of each other, but are non-superimposable.7 William Thomson, (Lord Kelvin),
first introduced this definition in 1883 at a lecture given to the Oxford University Junior
Scientific Club.8 It was not reintroduced into stereochemical literature until 1965 by
Mislow9 and 1966 Cahn, Ingold and Prelog.5
In 1899, Centnerswer studied a 1:1 mixture of (-)-bromosuccinic acid (Figure 1.1
left) and (+)-chlorosuccinic acid Figure 1.1 right).7, 10 He found that this mixture had
phase properties similar to those of the corresponding true racemic compounds for each
of the molecules. The mixture contained neither isomers nor enantiomers, but had an
“almost” or “pseudo” mirror-image relationship.7, 10
3

O

Br

Cl
(S)

OH

O

(R)

HO

HO

OH
H

H
O

O

Figure 1.1 Comparison of (left) chlorosuccinic acid and (right) bromosuccinic acid.

Most of the studies of quasiracemates, and the reasons for their formation, were
conducted in the 1960s and 1970s by A. Fredga.11 Fredga, in 1960, first used the term
“quasi-racemate” to distinguish this class of compounds.12 This research used melting
point phase diagrams and found that these sufficed to determine true racemic compounds,
racemic conglomerates, as well as quasiracemates. A racemic conglomerate is a mixture
of two types of crystals where each crystal is composed of only one enantiomer, but the
entire mixture has an equimolar amount of both enantiomers.3 This study provided clear
evidence for the presence of quasiracemates, identified necessary criteria for the selection
of sterically similar molecules, and used the molecular topology to design new
quasiracemates.11
In 1966, Jerome and Isabella Karle determined the structure of the
quasiracemates, (R)-2-(3-bromophenoxy) propionic acid and (S)-2-(3-methoxyphenoxy)
propionic acid (Figure 1.2).13 Their study of the pseudo inversion symmetry of this
quasiracemate proved to be one of the first investigations into packing motifs in
quasiracemates. The relationship of inversion packing to packing motif is now firmly
established.12

4

H3CO

O
(S)

CO2H

(R)

HO2C

O

Br

Figure 1.2 The quasiracemate of (R)-2-(3-bromophenoxy)propionic acid (right) and (S)2-(3-methoxyphenoxy)propionic acid (left).

In the 1990’s the late Margaret Etter, a pioneer in crystal engineering, studied
hydrogen bonding motifs in crystals. The research gave insight into the role of hydrogenbonding in controlling the structures of crystals. The use of graph-sets in describing these
motifs has been useful in understanding crystal structure and comparing and contrasting
sets of molecules. The terminology proposed by Etter et al., 1990 has been in use for the
past twenty years.14
In 2002, Fomulu et al. proposed several considerations for the design and
synthesis of quasiracemates using Fredga’s quasiracemates as a starting point.11 These
considerations include the fact that the two quasienantiomers need to be isosteric, unique
in chemical composition, and opposite in handedness. In addition, it is helpful to have a
high degree of similarity between the two components with the presence of hydrogen
donor and acceptor groups.11 These factors are relevant to our study of quasienantiomers
of oxadiazinanones.

Terminology and Basic Principles
Knowledge of basic terminology and principles are important to the
understanding of this research; therefore, it is worthwhile to include a review.
5

Enantiomers are compounds which have the same chemical formulas and the same
constitutions, but have different three-dimensional structures which are related by a
mirror plane as noted in Figure 1.3.

CH3

CH3

(S)

(R)
Br

HO2C

Br

H

CO2H
H

Figure 1.3 On the left is (S)-2-(2-bromo)propionic acid and on the right is (R)-2-(2bromo)propionic acid.

The IUPAC definition for a racemate is a composite of equimolar quantities of both
enantiomers of a compound.3, 7 Because of the equimolarity of the enantiomers, a racemic
mixture will not have optical activity as noted by Pasteur.6
A quasiracemate is a compound composed of two “almost” or similar
enantiomers. There is some ambiguity in the definition due to the use of the word,
“similar.” In an article by Fumulo et al., the definition is worded as “a molecular crystal
derived from a true racemate by a not-too-extensive change in the structure of one of the
two enantiomeric components.”11 How similar do the enantiomers need to be? The two
molecules in Figure 1.4 are almost alike differing only by the Br or Cl atom. The bromine
in the structure on the left has been replaced by chlorine in the structure on the right, as

6

indicated by the arrows. The two molecules in Figure 1.5 also differ at only one point, but
the difference involves many more atoms.

CH3

CH 3

(S)
HO 2C

(R)

Cl

Br
H

CO 2H
H

Figure 1.4 Quasienantiomers which differ only because one molecule has a Cl atom
instead of a Br atom. The dotted line represents a mirror plane.

O

Ph

O

O
O

N

S

Me

O
O
Ph

O

N

O
O

S
O

O
Si

Figure 1.5 Quasienantiomers which only differ in the presence of a methyl group in
one(top) and a tri-isopropyl silyl ether functional group in the other (bottom). The dotted
line represents a mirror plane.7

Comparing Figures 1.4 and 1.5, one can see there is a much greater difference
between the quasienantiomers in Figure 1.5 than those in Figure 1.4. The methyl (Me)
7

group in the structure on top in Figure 1.5 has been exchanged for a tri-isopropyl silyl
ether group in the bottom structure. Although all of the other atoms in the structures are
identical in identity and location, the molecules seem to be quite different.
It is difficult, therefore, to define quasiracemate in a very specific manner. To
crystallographers, the definition most generally refers to a crystal comprised of
compounds that are very nearly enantiomers with differences of a small number of atoms.
This is a very “loose” definition as the “small number” can vary greatly. To synthetic
chemists, the difference in the quasienantiomers could be a small such as the difference
in a methyl and an isopropyl group or, at the other extreme, the difference could be very
large like the difference between a methyl and a polystyrene group. In the present
research, a general supposition has been made that the quasienantiomers are closely
related and able to form a co-crystal.
Crystallography has a unique vocabulary and a short review may prove to be
helpful. Crystals are an arrangement of atoms repeating in a three-dimensional pattern.15
The arrangement can go infinitely in all directions by repeating the basic unit of the
crystal. This basic unit is called the unit cell. Each unit cell has the same atomic contents
arranged in the same way.

The atoms within the unit cell can be further reduced to an

asymmetric unit. An asymmetric unit is the smallest unit of volume that contains all of
the structural information about the crystal. By applying symmetry operations to the
asymmetric unit, such as inversion, translation, reflection, etc., the unit cell can be
reproduced. The number of molecules in the asymmetric unit is designated by Z’ and the
number of molecules in the unit cell is designated as Z.15

8

Oxadiazinanone-What is in a Name?
The typical nomenclature of the oxadiazinanones can be confusing as one looks
over the literature of the last thirteen years. This is evidenced by looking at the titles of
papers authored or co-authored by Dr. G.M. Ferrence. In 2001, research involving
3,4,5,6-tetrahydro-2-H-1,3,4-oxadiazin-2-one was reported.16 In articles published in
2002, research was also published reporting N3-substituted [1,3,4]-oxadiazinan-2-ones.17
In 2004, one finds research on a group of compounds called oxadiazinones.18 In 2008,
two papers were written on research involving chirality and substituted 1,3,4oxadiazinan-2-ones.19a,19b In 2009 a paper was published on (5S,6R)-4-isopropyl-5methyl-6-phenyl-3-propanoyl-2H-1,3,4-oxadiazinan-2-one.20 A slight variation is found
in 2009 when the compound is a thione instead of a ketone. In this case the nomenclature
changes to (5S,6R)-5-methyl-6-phenyl-4-propyl-1,3,4-oxadiazinane-2-thione.21 Why the
differences? What do the different names mean?
IUPAC recommends using the Hantzsch-Widman nomenclature in the naming of
heterocycles.22 The rings are named by combining prefixes with a stem. In the case of
oxadiazinanones, the prefix ‘oxa’ refers to the oxygen atoms in the ring and the ‘az’ to
the nitrogen atoms in the ring; the ‘di’ reflects the fact there are two nitrogen atoms. The
order of the names of the heteroatoms is dictated by IUPAC as O, N, and, then, S. Other
atom preferences are listed in the literature.23 Typically the ‘az’ would be ‘aza,’ but
phonetics dictates the omission of the final ‘a.’ This type of omission is called eliding.
The stem for a saturated 6-member heterocycle with nitrogen and oxygen in the ring is
‘inane’ but in the case of these compounds the final ‘e’ is omitted, again, for phonetic
reasons. In some cases the stem ‘inane’ is changed to ‘ine’ and the saturated atoms that
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are present in the compound are denoted by using terms such as ‘tetrahydro,’ or
‘dihydro.’ Because oxadiazinanones are ketones, the name of the compound ends in
‘one.’ The numbering in heterocyclic rings becomes necessary when substituents are
placed on the ring. The numbering begins with a hetero-atom, and then the substituents
are numbered so that the lowest combination of numbers is assigned. The substituents are
placed in alphabetical order. The positions of the substituents play no role in the order of
the numbering. The substituents are included in alphabetical order preceded by the
number of the atom to which they are attached.23 In addition to these rules, unsaturated
atoms located in the ring are designated by using ‘H.’ This reflects that the parent hydride
would have hydrogen atoms in this position.
Using the compound in Figure 1.6 as an example, the proper nomenclature will be
discussed. In this heterocycle the chirality is described by (5S,6R).

O
O1
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5
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NH

4N

(S)

Figure 1.6 Line drawing of (5S,6R)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one.

The substituents are listed in alphabetical order with the number of the atom to which
they are attached preceding the name of the substituent. The order of the atom numbers is
chosen by starting with the oxygen atom as atom 1 and then numbering the rest. This
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numbering scheme results in the lowest combination of position-numbers of heteroatoms
as possible. The 2H indicates an atom where the parent hydride would have hydrogen
atoms affixed, but it does not in this molecule because of the carbonyl group. The “1,3,4oxadiaz” portion of the name refers to the oxygen atom and two nitrogen atoms in the
heterocycle. The substituents are arranged in alphabetical order preceded by the atom
number to which they are attached. The prefix, “inan,” refers to a saturated heterocycle
containing nitrogen. The stem, “2-one,” refers to the fact that this is a ketone with the
carbonyl on atom 2.
Why Study Quasiracemates?
Some reasons for the study of quasienantiomers given in a review by Zhang and
Curran are that they can be used as tools for enantiomer identification, enantiomer
analysis, separation of chemical components and enantiomer synthesis.7 Although all of
these pragmatic uses are valuable, the current study is more esoterically focused on how
and why oxadiazinanones form quasiracemates. This is related to the discussion of
Fomolu and co-workers about the study of quasiracemates in the field of supramolecular
chemistry. Using comparisons of quasiracemate, enantiomer, and racemate crystals, the
molecular architecture can be studied.11 The database of quasiracemic crystals needs to
be as large as possible in order to determine general principles which cause the
crystallization of quasiracemic crystals.
Additionally, oxadiazinanones have been synthesized fairly easily using methods
developed by Hitchcock and his group.24, 25 Decent yields have been reported. The
compounds are easily purified with flash chromatography. Optically pure norephedrine or
ephedrine starting materials result in optically pure substituted oxadiazinanones.
11

Previous Quasiracemic Crystal Research
The research group of Dr. Shawn Hitchcock at Illinois State University has
synthesized and studied a variety of oxadiazinanones as a route to forming chiral
auxiliaries for pharmaceutical studies.25 In an effort to understand some principles of
crystal structure and chirality, Kate Edler used these immediately-available
oxadiazinanones in her research.26 In the course of the research, serendipitously, she
mixed together norephedrine-based (5S,6R)-4-isopropryl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one and (5R,6S)-4-cyclohexyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan2-one in approximately equal molarities. These crystals resulted in the first of the
quasiracemic oxadiazinanone crystals studied by the Ferrence group.26
Ignoring epimers, there are two oxadiazinanone enantiomers for each
norephedrine derived N-4-substituted variant. Figure 1.7 shows a line drawing of
(5R,6S)-6-phenyl-4-R-(1,3,4)-oxadiazin-2-one. The arrow points to the nitrogen with the
substituted variant.
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Figure 1.7 Line drawing of (5R,6S)-4-R-5-methyl-6-phenyl-1,3,4-oxadiazinan-2-one.
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For example, using the cyclopentyl functional group, the two oxadiazinanone
structures in Figure 1.8, when crystallized, form a racemic crystal.
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(S)

CH3

CH3

Figure 1.8 Line drawing of (left) (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one and (right) (5S,6R)-4-cyclopentyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one.

If an isopropyl group is substituted for the cyclopentyl group (structure on the left
in Figure 1.8) and a cyclohexyl group for the cyclopentyl group (structure on the right),
the resulting compounds are shown in Figure 1.9. These compounds cocrystallize
forming a quasiracemic crystal.
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Figure 1.9 Line drawings of (left) (5R,6S)-4-isopropryl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one and (right) (5S,6R)-4-cyclohexyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one.
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The fact that the oxadiazinanones in Figure 1.9 formed quasiracemic crystals begs
the question: would other oxadiazinanones do so as well? To further explore the
possibility, it was necessary to acquire a number of oxadiazinanones which varied at the
N4 position in both (5S,6R) and (5R,6S) configurations.
The synthesis of these compounds uses either ephedrine (for methyl-substitution)
or norephedrine as a starting reactant.27 The resulting oxadiazinanone quasienantiomers
are then mixed and crystallized in an attempt to form the corresponding quasiracemate.
Finally, the crystal structures are studied in an attempt to determine what causes some
oxadiazinanone quasienantiomers to cocrystallize and others to fractionally crystallize.
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CHAPTER II
EXPERIMENTAL
Synthesis of Oxadiazinanones Used in Crystallographic Studies
All oxadiazinanone compounds used in this research were either acquired from
the lab of Dr. Shawn Hitchcock or synthesized using procedures, or adaptations thereof,
devised by the Hitchcock group.27 The compound, (5R,6S)-4-cyclopentyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one, and its precursors are newly-synthesized products.
The synthesis of the ethyl derivative of the oxadiazinanone and the n-butyl derivative of
the oxadiazinanone, instead of producing the desired oxadiazinanones, resulted in newlysynthesized noncyclized compounds. In addition to these newly-synthesized compounds,
two new quasiracemates were formed when (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl2H-1,3,4-oxadiazinan-2-one was crystallized with (5S,6R)-4-cyclohexyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one and separately with (5S,6R)-4-isopropyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one.
The synthesis of oxadiazinanones includes four main steps: alkylation,
nitrosation, hydrazine-formation, and cyclization. Figures 2.1, 2.3, 2.5, and 2.6 show the
steps in the reaction using the cyclopentane derivative as an example: Figure 2.2 gives
the mechanism for the reductive alkylation. Table 2.1 shows which alkyl groups were
added to N4 as a substituent.
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Figure 2.1 Step 1: Reductive alkylation of (1S,2R) norephedrine.
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Figure 2.2 Mechanism for the reductive alkylation of an amine.28

Table 2.1 Aldehydes and ketones used in the synthesis of N4 substituted norephedrine.
N4 Substituent
ethyl
n-propyl
isopropyl
n-butyl
cyclohexyl
cyclopentyl

Reactant
acetaldehyde
propanal
acetone
butanal
cyclohexanone
cyclopentanone
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Figure 2.3 shows the reaction for the nitrosation of the alkylated norephedrine and
the mechanism for the reaction is shown in Figure 2.4.
O
H

OH
(S)
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N
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N

THF

Nitrosated cyclopentyl
derivative of
R)norephedrine
S
,2
(1

Cyclopentyl derivative
of (1S,2R)norephedrine

Figure 2.3 Step 2: Nitrosation of the alkylated derivative of (1S,2R) norephedrine.
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Figure 2.4 Mechanism for the nitrosation of an alkylated norephedrine.28
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The nitrosate of the alkyl derivative of the norephedrine is part of a group of
compounds known to be carcinogenic, so great care must be used to avoid contact with
the compound during the synthesis.29
At the conclusion of Steps 1 and 2, 1H nuclear magnetic resonance spectroscopy
(1H NMR) analysis is used to ascertain that the proper product is formed in sufficient
purity to continue the synthesis. When the product is not what is expected or is in low
yield, typically, the step can be repeated to obtain the desired product and the synthesis
can continue. When purification of the product is needed, flash chromatography is
utilized.
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N

OH
(S)

(R)

LiAlH4

(S)

N

NH2

OH
(R)

N

THF

nitrosated cyclopentyl
derivative of
(1S,2R) norephedrine

hydrazine of cyclopentyl
derivative of
(1S,2R) norephedrine

Figure 2.5 Step 3: Hydrazine-formation from the reduction of the nitrosate of the alkyl
derivative of (1S,2R) norephedrine.
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(5R,6S)-4-cyclopentyl-5-methyl6-phenyl-2H-1,3,4-oxadiazinan-2-one

hydrazine of cyclopentyl
derivative of (1S,2R) norephedrine

Figure 2.6 Step 4: Cyclization of the hydrazine forming the 1,3,4 oxadiazinanone.

Steps 3 and 4 are completed with as little delay between them as possible because
the hydrazine is not stable. 1H NMR testing is typically not done after Step 3 as the
hydrazine cannot be purified at this point and remain stable, so the synthesis must
continue. Bentley, in his thesis, proposed mechanisms for the third and fourth steps of the
procedure; these will not be further explored here.28
Change in 1H NMR After Nitrosation of Alkyl Derivative
The rotamer diastereomers for the nitrosate are shown in Figure 2.7. The rotamer
on the right results in having a doublet at 0.8 ppm in the 1H NMR spectrum. The rotamer
on the left results in a second doublet further downfield at 1.6 due to the shielding of the
oxygen atom in the nitrosate. According to Hitchcock, Casper et al.29 the two rotamers
exist because the resonance of the N=O bond in the structure creates a barrier to rotation
of the N-N=O moiety. The N-N bond does not rotate until very high temperatures are
obtained so both rotamer diastereomers occur simultaneously in the nitrosate of the
alkylated derivative of norephedrine. These two rotamers help to verify the presence of
the nitrosate.
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The 1H NMR spectra of the alkylated derivative, as seen in Figure 2.8, has a
doublet at 0.8 ppm indicating the presence of the methyl group. However, when the Nnitroso amine is formed in the second step of the synthesis, the 1H NMR spectra in Figure
2.9 shows two doublets for the methyl group—one doublet at 0.83 ppm and one
downfield at 1.6`. This results from the formation of two diastereomeric rotamers (Figure
2.7) which exist as major and minor species in the product.
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Figure 2.7 The (E)-rotamer (left) and the (Z)-rotamer (right) of the nitrosamines of the
cyclopentyl derivatives of (1S,2R) norephedrine.
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Figure 2.8 1H NMR spectrum of the cyclopentyl derivative of (1S,2R) norephedrine.
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Figure 2.9 1H NMR spectrum of the nitrosate of the cyclopentyl derivative of (1S,2R)
norephedrine. Note the presence of the two doublets caused by the two different nitrosate
rotamers.

Experimental Procedure for the Synthesis of (5R,6S)-4-Cyclopentyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one, 1
Alkylation: (1S,2R) norephedrine (10.00 g, 66.13 mmol) and cyclopentanone (7.00 g,
83.2 mmol) were added to a nitrogen-purged, 1 L round-bottom flask with ethanol (100
mL). The mixture was refluxed for 24 hours, cooled in an ice bath and NaBH4 (6.26 g,
165 mmol) was added over a period of approximately 30 minutes. The flask was removed
from the ice and ethanol was added (100 mL). After the mixture was stirred for an
additional 2.5 hours, 1M NaOH (100 mL, 100 mmol) was added. Ethanol was removed
from the solution using rotary evaporation, and the product was extracted with ethyl
acetate, washed with brine, and dried over sodium sulfate resulting in the cyclopentyl
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derivative of (1S,2R) norephedrine (13.73 g, 76.24 mmol). 1H NMR spectroscopy was
used to ascertain the purity of the sample, and it was determined that the product was not
fully alkylated. The product was then refluxed overnight under the same conditions and
with the same reagents as described previously resulting in the desired product.
Nitrosation: The cyclopentyl derivative of (1S,2R) norephedrine was nitrosated by adding
3M HCl (25 mL, 75 mmol) to the alkylated norephedrine. Approximately 60 mL of
tetrahydrofuran (THF) was added, and the mixture was stirred. To the mixture NaNO2
(5.5 g, 79 mmol) was added. The solution turned pink. The reaction was allowed to
proceed for 4 days. Sodium bicarbonate (saturated solution) was added to reach a pH of
8. THF was removed by rotary evaporation. The final product was extracted with ethyl
acetate, washed with brine and dried over Na2SO4. The ethyl acetate was removed by
rotary evaporation resulting in the nitrosated cyclopentyl derivative of (1S,2R)
norephedrine (8.19 g, 33.0 mmol). One gram was removed for further research and the
rest of the product was reduced.
Reduction: Hexanes (200 mL) were added to a flame-dried, nitrogen-purged, 2 L roundbottom flask. Lithium aluminum hydride (2.29 g, 60.3 mmol) was added to the flask
followed by the addition of THF (approximately 600 mL). The nitrosated cyclopentyl
derivative of (1S,2R) norephedrine (7.19 g, 29.0 mmol) was dissolved in THF (100 mL)
and added, dropwise, to the flask. The reaction was gently refluxed for three hours, and,
then, cooled in an ice bath. Then, 1M NaOH (200 mL, 200 mmol) was added. Rotary
evaporation was used to remove the THF. The product was extracted with ethyl acetate,
washed with Rochelle’s solution and brine, and dried over NaSO4. The ethyl acetate was
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removed by rotary evaporation resulting in the hydrazine, an oily, yellow product (5.24 g,
22.4 mmol).
Cyclization: The hydrazine was dissolved in hexanes (144 mL) in a flame-dried, nitrogenpurged 1 L round-bottom flask. Diethyl carbonate (2.98 mL, 24.6 mmol) was added to
the flask and the solution was refluxed under nitrogen for 16 hours. The resulting product
was cooled in an ice bath and the hexanes were removed by rotary evaporation. The
resulting product was dissolved in ethyl acetate (123 mL), washed with 1M HCl (3 x
15mL) and brine, and dried over sodium sulfate. Rotary evaporation was used to remove
the ethyl acetate and a yellow, oily solid was obtained (5.16 g). Crystallization of the
final product was achieved by dissolving the product in ethyl acetate and adding hexanes
as an anti-solvent, resulting in a crystalline product (1.18 g, 4.53 mmol). The percent
yield was 6.85%.
Experimental Procedure for the Intended Synthesis of (5R,6S)-4-Ethyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one, 5
The synthesis of (5R,6S)-4-ethyl-5-methyl-6-phenyl-2H-1,3,4-oxodiazinanan-2ne proved to be problematic. Using acetaldehyde was difficult because it has such a low
boiling point that it evaporated before the reaction occurred. Thus acetic anhydride was
used, producing an amide derivative which was then reduced by NaBH4 and I2 followed
by nitrosation.24 This method resulted in a mixture of the amide and amine and other
unknown compounds. Two grams of the amide were produced to use for future study.
The initial procedure was once again tried with a large excess of acetaldehyde. The
acetaldehyde was stored in a freezer at 0 °C prior to use. Nitrosation followed and flash
chromatography was used to purify the nitrosated compound. The 1H NMR spectrum
24

indicated the proper compound was made. However, after the product was reduced,
cyclized and then purified using flash chromatography, X-ray diffraction analysis
determined the structure in Figure 2.10. This structure indicates the cyclization had not
been completed. The specifics of the synthesis follow.
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Figure 2.10 Line drawing of 5. This is not an oxadiazinanone, but the product of an
oxadiazinanone reaction which did not cyclize.

Alkylation: (1S,2R) norephedrine (10.00 g, 66.13 mmol) and acetaldehyde (7.4 mL, 130
mmol) and ethanol (100 mL) were added to a nitrogen-purged, 1L round-bottom flask.
The syringe used to add the acetaldehyde was placed in the freezer before use in an
attempt to reduce the evaporation of the aldehyde. The mixture was refluxed for 24 hours
and cooled in an ice bath. NaBH4 (6.24 g, 165 mmol) was added over a period of
approximately 30 minutes. The flask was removed from the ice and ethanol was added
(100 mL). After the mixture was stirred for an additional 2.5 hours, 1M NaOH (100 mL,
100 mmol) was added. Ethanol was removed using rotary evaporation. The resulting
product was extracted with ethyl acetate, washed with brine, and dried over sodium
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sulfate resulting, in the ethyl derivative of (1S,2R) norephedrine (11.91 g, 66.50 mmol).
1

H NMR analysis revealed the product was pure and nitrosation could take place.

Nitrosation: The ethyl derivative of (1S,2R) norephedrine was nitrosated by, first, adding
3M HCL (25 mL, 75 mmol) to the alkylated product and then adding THF (50 mL). The
mixture was stirred. Sodium nitrite (5.6 g, 79 mmol) was added and the reaction was
allowed to stir overnight. The solution was orange-brown in color. Sodium bicarbonate
(saturated solution, 50 mL) was added until the solution reached a pH of 8. THF was
removed by rotary evaporation. The final product was extracted with ethyl acetate,
washed with brine, and dried over Na2SO4. The ethyl acetate was removed by rotary
evaporation resulting in the nitrosated ethyl derivative of (1S,2R) norephedrine. 1H NMR
spectroscopy indicated the product needed purification. This was accomplished using
flash chromatography resulting in the final crystalline product. (3.97 g, 19.1 mmol).
Reduction: Hexanes (200 mL) were added to a flame-dried, nitrogen-purged, 2L roundbottom flask. Lithium aluminum hydride (0.9737 g, 38.15 mmol) was added to the flask
followed by the addition of THF (600 mL). The nitrosated ethyl derivative of (1S,2R)
norephedrine (3.97 g, 19.1 mmol) was dissolved in THF (100 mL) and added, drop-wise,
to the flask. The reaction was gently refluxed for three hours, cooled in an ice bath, and
1M NaOH (200 mL, 200 mmol) was added. Rotary evaporation was used to remove the
THF, and the product was extracted with ethyl acetate andwashed with Rochelle’s
solution. Then it was washed with brine, and dried over NaSO4. The ethyl acetate was
removed by rotary evaporation resulting in the hydrazine, an oily, yellow product (2.49 g,
12.8 mmol).
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Cyclization: The hydrazine was dissolved in hexanes (144 mL) in a flame-dried and
nitrogen-purged 1L round-bottom flask. Diethyl carbonate (1.7 mL, 21 mmol) was added
to the flask and the solution was brought to reflux. Lithium hydride (0.33 g, 42 mmol)
was added slowly and the solution was refluxed under nitrogen overnight. The resulting
product was cooled and hexanes were removed by rotary evaporation. The resulting
product was dissolved in ethyl acetate (123 mL), washed with 1M HCl, washed with
brine, and dried over sodium sulfate. Rotary evaporation was used to remove the ethyl
acetate and a yellow, oily compound was obtained (5.16 g). The resulting product was
dissolved in ethyl acetate and hexanes were added to cause the product to crystallize
(2.19 g, 9.95 mmol). The percent yield was 15.1%.
Experimental Procedure for the Intended Synthesis of (5R,6S)-4-Ethyl-5-methyl-6phenyl-2H-1,3,4-oxadianinan-2-one, 6
In an attempt to synthesize (5R,6S)-4-ethyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinanan-2-one using standard literature procedures27 the compound depicted in the
ChemDraw30 figure in Figure 2.11 was synthesized and was identified using X-ray
diffraction indicating the cyclization reaction had not gone to completion.
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Figure 2.11 Line drawing of 6. This is not an oxadiazinanone, but, instead is the product
of an oxadiazinanone reaction which did not cyclize.
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Alkylation: (1S,2R) norephedrine (10.00 g, 66.13 mmol), butanal (7.2 mL, 80 mmol) and
ethanol (100 mL) were added to a nitrogen-purged, 1L, round-bottom flask. The mixture
was refluxed for 24 hours and cooled in an ice bath. NaBH4 (6.26 g, 165 mmol) was
added over a period of 30 minutes. The flask was removed from the ice and ethanol was
added (100 mL). The mixture was stirred for an additional 2.5 hours, and 1M NaOH (100
mL, 100 mmol) was added. Ethanol was removed from the solution using rotary
evaporation, and the product was extracted with ethyl acetate, washed with brine, and
dried over sodium sulfate resulting in the n-butyl derivative of (1S,2R) norephedrine. The
product was purified with flash chromatography.
Nitrosation: The n-butyl derivative of (1S,2R) norephedrine was nitrosated by dissolving
the alkylated norephedrine in 3M HCl (25mL, 75mmol. THF (60 mL) was added and the
mixture was stirred while NaNO2 (5.5 g, 79 mmol) was added. The reaction proceeded
under reflux overnight. Sodium bicarbonate (saturated solution) was added to the flask
until a pH of 8 was reached. Rotary evaporation was used to remove the THF. The final
product was extracted with ethyl acetate, washed with brine, and dried over Na2SO4. The
ethyl acetate was removed by rotary evaporation resulting in the nitrosated n-butyl
derivative of (1S,2R) norephedrine. Flash chromatography was used to purify the product
(5.13 g, 21.7 mmol).
Reduction: Hexanes (200mL) were added to a flame-dried, nitrogen-purged, 2L roundbottom flask. Lithium aluminum hydride (2.47 g, 65.1 mmol) was added to the flask
followed by the addition of THF (135 mL). The nitrosated n-butyl derivative of (1S,2R)
norephedrine (5.13 g, 21.7 mmol) was dissolved in THF (50 mL) and added, dropwise, to
the flask. The reaction was refluxed for an additional two hours. The reaction was cooled
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in an ice bath and 3M NaOH (40 mL, 100 mmol) was added. THF was removed using
rotary evaporation. The hydrazine was extracted with ethyl acetate, washed with
Rochelle’s solution and brine, and dried over NaSO4. The ethyl acetate was removed by
rotary evaporation resulting in an oily, yellow product (4.83 g, 21.7 mmol).
Cyclization: The hydrazine was dissolved in hexanes (200 mL) in a nitrogen-purged,
flame-dried, 1L round-bottom flask. Diethyl carbonate (2.82 mL, 23.8 mmol) was added
to the flask and the solution was brought to reflux under nitrogen. Lithium hydride (0.35
g, 44 mmol) was added, and the solution was refluxed overnight. The resulting product
was cooled in an ice bath, and hexanes were removed with rotary evaporation. The
resulting product was dissolved in ethyl acetate (123 mL), washed with 1M HCl, then
with brine, and dried over sodium sulfate. Rotary evaporation was used to remove the
ethyl acetate, and a yellow, oily solid was obtained (4.41 g). The oil was purified using
flash chromatography resulting in a white crystalline product (5.17 mmol, 7.82% yield).
Crystallization Procedure
Single crystals were formed using vapor diffusion. If a pure compound was being
crystallized, a sample of approximately 0.008 g was placed in an uncapped inner vial in
0.5 mL of solvent. If a racemate or quasiracemate was being crystallized, a mixture of the
compounds was used with a total weight of approximately 0.008 g. Since the molecular
weights of the oxadiazinanones are similar, this provided nearly equimolar solutions with
concentrations of approximately 3 x 10-5 M for each component. If just one compound
was being crystallized, this provided a 6 x 10-5 M concentration. Into an outer vial was
placed 2.5 mL of the anti-solvent, hexanes (boiling point, 69 °C. The crystals are not
soluble in hexanes. The outer vial was then closed, allowing the solvent and anti-solvent
29

to equilibrate by vapor diffusion. Ethyl acetate (boiling point, 77 ⁰C) was used as the

solvent. In this system the hexanes diffuse into the inner vial. At the same time there is a
slow diffusion of the solvent out of the inner vial into the hexanes. The oxadiazinanones
are not as soluble in hexanes as in ethyl acetate. Because the diffusion taking place in the
system increases the concentration of hexanes in the inner vial, crystals slowly form.31 If
crystallization of the oxadiazinanones did not happen after 2 to 3 days, the hexanes were
removed and replaced with fresh hexanes. Usually, crystals formed within 2 to 3 days at
room temperature.
X-Ray Diffraction
X-ray structures were obtained by selecting a suitable crystal using a dissecting
microscope. The dimensions of most crystals were approximately 0.2 mm to 0.4 mm on
each side. The crystals were then mounted using mineral oil as an adherent on MiTeGen
Micromounts with loops or MicroMesh aperatures. The mount was attached to the
goniometer head and mounted on a Bruker Apex II diffractometer. Mo-Kα radiation
(λ=0.71073 Å) was used for the collection of the data. The sample was generally kept at
100K during data collection. For some samples, additional information was gained by
varying the temperature during collection as indicated in the experimental details about
each compound. All data were collected using the software program, SAINT, and refined
using SMART+.32 Solution and data analysis were completed using the WinGX software
package.33 The structures were solved using direct methods employing the programs,
SIR200434 or SuperFlip.35 The refinement was accomplished using SHELXL-2012.36 The
non-hydrogen atoms were refined anisotropically and, in most cases, the hydrogen atoms
were assigned using a riding-model approximation. Hydrogen atoms attached to nitrogen
30

atoms were freely refined unless indicated otherwise in the experimental details for each
compound.

31

CHAPTER III
CRYSTALLOGRAPHIC RESULTS
Crystallographic Details of (5R,6S)-4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one, 1
Figure 3.1 shows a ChemDraw30 depiction of (5R,6S)-4-cyclopentyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one (1).

O
O
(S)

NH
(R)

N

CH3

Figure 3.1 Line diagram of 1.

The dimensions of the crystal used for X-ray diffraction were 0.360 mm x 0.270 mm x
0.210 mm. The sample was g kept at 100K during the diffraction experiment. Shelxl201236 was used for refinement. The unit cell parameters were obtained from a leastsquares refinement of 4581 unique reflections out of the 17571 reflections collected. The
crystal is orthorhombic and crystallizes in the P212121 space group. The cell lengths are:
a = 8.4171(3) Å, b = 9.0618(4) Å, and c = 36.7815(13) Å. The volume of the cell is
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2805.47 Å3 and ρ = 1.233 g/cm3. Z’ is 2 and Z is 8. Diffraction data were measured
between θmin = 1.107° and θmax = 25.352°. The limiting indices were -10 ≤ h ≤ 10, -10 ≤ k
≤ 10, and -44 ≤ l ≤ 44. All hydrogen atoms attached to nitrogen were freely refined and
all other hydrogens were refined using the riding-model approximation. Convergence
was reached on the full-matrix least-squares refinement of F2. The R1-factor is 0.0432
and wR2 is 0.1029. Figure 3.2 shows an ORTEP33 depiction of 1. The ellipsoids are at
50% and the hydrogen atoms have been omitted for clarity. The hydrogen bonds are
shown as dotted lines.

Figure 3.2 Ellipsoid depiction of 1.

The bond lengths, bond angles and torsion angles of the central oxadiazinanone
ring as well as any carbon atoms attached to the ring are shown in Tables 3.1-3. Table 3.4
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shows the hydrogen bond lengths. Molecule 1 refers to the molecule with the lower range
of atom numbers. This is the molecule on the right side in Figure 3.2.

Table 3.1 Bond lengths of the central oxadiazinanone rings in the asymmetric unit of 1.
Atoms (Molecule 1)

Distance (Å)

Atoms (Molecule 2)

Distance (Å)

O1-C2
O1-C6
C2-O19
C2-N3
N3-N4
N4-C14
N4-C5
C5-C6
C5-C13
C6-C7

1.356(4)
1.463(4)
1.223(4)
1.336(4)
1.424(4)
1.479(4)
1.470(4)
1.542(5)
1.516(5)
1.499(5)

O51-C52
O51-C56
C52-O69
C52-N53
N53-N54
N54-C64
N54-C55
C55-C56
C55-C63
C56-C57

1.356(4)
1.455(4)
1.224(4)
1.338(4)
1.428(4)
1.490(4)
1.466(4)
1.534(5)
1.517(5)
1.507(5)

Table 3.2 Bond angles of the central oxadiazinanone rings in the asymmetric unit of 1.
Atoms (Molecule 1)
C6-O1-C2
O1-C2-N3
O1-C2-O19
O19-C2-N3
C2-N3-N4
N3-N4-C5
C14-N4-C5
N4-C5-C13
C13-C5-C6

Angle (°)
121.1(3)
118.7(3)
117.5(3)
123.8(3)
125.9(3)
108.5(2)
114.9(3)
109.4(3)
114.3(3)

Atoms (Molecule 2)
C56-O51-C52
O51-C52-N53
O51-C52-O69
O69-C52-N53
C52-N53-N54
N53-N54-C55
C64-N54-C55
N54-C55-C63
C63-C55-C56

34

Angle (°)
121.6(3)
118.6(3)
117.9(3)
123.5(3)
124.7(3)
107.0(2)
117.0(3)
110.0(3)
114.1(3)

Table 3.3 Torsion angles of the central oxadiazinanone rings in the asymmetric unit of 1.
Atoms (Molecule 1)

Torsion (°)

C6-O1-C2-N3
C6-O1-C2-O19
C2-O1-C6-C5
C2-O1-C6-C7
O1-C2-N3-N4
O19-C2-N3-N4
C2-N3-N4-C5
C2-N3-N4-C14
N3-N4-C5-C6
N3-N4-C5-C13
C14-N4-C5-C6
C14-N4-C5-C13
N4-C5-C6-O1
N4-C5-C6-C7

1.5(4)
179.1(3)
-26.7(4)
-151.2(3)
-4.1(5)
178.4(3)
32.5(4)
-92.5(4)
-55.3(3)
70.7(3)
65.8(3)
-168.2(3)
54.1(3)
175.0(3)

Atoms (Molecule 2)
C56-O51-C52-N53
C56-O51-C52-O69
C52-O51-C56-C55
C52-O51-C56-C57
O51-C52-N53-N54
O69-C52-N53-N54
C52-N53-N54-C55
C52-N53-N54-C64
N53-N54-C55-C56
N53-N54-C55-C63
C64-N54-C55-C56
C64-N54-C55-C63
N54-C55-C56-O51
N54-C55-C56-C57

Torsion (°)
-7.4(5)
172.0(3)
-20.4(4)
-143.8(3)
1.1(5)
-178.3(3)
33.0(4)
-94.1(4)
-58.8(3)
67.4(3)
63.1(3)
-170.8(3)
54.1(3)
175.2(3)

Table 3.4 Donor-Acceptor Hydrogen bond lengths in 1.
Donor-Acceptor

Distance, D-A (Å)

N53-O19

2.879

O69-N3

2.888

Bonding Motif
Different Enantiomorph

Crystallographic Details of Racemic 4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one, 2
Compound 2 was prepared by combining equal amounts of each enantiomer of 4cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one. The two enantiomers are
shown in Figure 3.3. The enantiomer on the left is the ChemDraw30 depiction of (5R,6S)
configuration and on the right is the ChemDraw30 depiction of (5S,6R) enantiomer.
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Figure 3.3 Line drawings of the two enantiomers of 2.
The temperature was 292 K. Shelxl-201236 was used for refinement. The unit cell
parameters were obtained from a least-squares refinement of 2460 unique reflections out
of the 19297 reflections collected. The crystal is monoclinic and crystallizes in the P21/c
space group. The cell lengths are: a = 9.1808(3) Å, b = 15.7560(5) Å, and c = 9.7293(3)
Å. The angles of the cell are: α = 90°, β = 106.132(2)°, and γ = 90°. The volume of the
cell is 1351.95 Å3 and ρ = 1.279 g/cm3. Z’ is 1 and Z is 4. Diffraction data were
measured between θmin = 2.309° and θmax = 25.300°. The limiting indices were -11 ≤ h ≤
11, -18 ≤ k ≤ 18, and -11 ≤ l ≤ 11. All hydrogen atoms attached to nitrogen were freely
refined, and all other hydrogens were refined using the riding-model approximation.
Convergence was reached on the full-matrix least squares refinement of F2. The R1 factor
is 0.0381 and wR2 is 0.0926.
Figure 3.4 shows an ORTEP33 depiction of 2. The ellipsoids are at 50% and the
hydrogen atoms have been omitted for clarity. The hydrogen bonds are shown as dotted
lines.
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Figure 3.4 Ellipsoid depiction of asymmetric unit of 2.

The bond lengths, bond angles and torsion angles of the central oxadiazinanone
ring as well as any carbon atoms attached to the ring are shown in Tables 3.5- 3.7. Each
oxadiazinanone structure has two hydrogen bonds in the asymmetric unit. Hydrogen
bond distances and angles are shown in Table 3.8.
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Table 3.5 Bond lengths in the central oxadiazinanone ring of 2.
Atoms

Bond Length (Å)

O1-C2
O1-C6
C2-N3
C2-O20
N3-N4
N4-C5
C5-C6
C7-C8

1.354(2)
1.446(2)
1.333(2)
1.227(2)
1.429(2)
1.473(2)
1.533(2)
1.391(3)

Table 3.6 Bond angles of the central oxadiazinanone ring of 2.
Atoms

Angle (°)

C6-O1-C2
O1-C2-N3
O1-C2-O19
O19-C2-N3
C2-N3-N4
N3-N4-C5
C14-N4-C5
N4-C5-C13
C13-C5-C6
C5-C6-O1

118.5(1)
118.8(1)
117.7(1)
123.4(1)
127.5(1)
108.7(1)
114.9(1)
109.9(1)
113.0(1)
108.9(1)
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Table 3.7 Torsion angles of the central oxadiazinanone ring in the asymmetric unit of 2.
Atoms

Torsion (°)

C6-O1-C2-N3
C6-O1-C2-O20
C2-O1-C6-C5
C2-O1-C6-C7
O1-C2-N3-N4
O19-C2-N3-N4
C2-N3-N4-C5
C2-N3-N4-C14
N3-N4-C5-C6
N3-N4-C5-C13
C14-N4-C5-C6
C14-N4-C5-C13
N4-C5-C6-O1
N4-C5-C6-C7
C13-C5-C6-O1
C13-C5-C6-C7

-7.7 (2)
174.5(1)
40.0(2)
165.4(1)
-6.4(2)
171.3(1)
-15.3(2)
111.3(2)
47.0(1)
-77.9(1)
-76.6(1)
158.5(1)
-60.4(1)
178.8(1)
62.7(1)
-58.1(2)

Table 3.8 Donor-Acceptor Hydrogen bond lengths in 2.
DonorAcceptor
N3-O19

Distance, D-A (Å)

Bonding Motif

2.824

Same enantiomorph

Crystallographic Details of Quasiracemate of (5R,6S)-4-Cyclopentyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one and (5S,6R)-4-Isopropyl5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one, 3
ChemDraw30 depictions of the quasienantiomers used to produce 3 are shown in
Figure 3.5. X-ray diffraction was used to confirm the presence of quasiracemates.

39

O

O

H

H
(S)

(R)

N

O

N

O

(R)

N

(S)

N

CH3

CH3

Figure 3.5 Line drawings of (left) (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H- 1,3,4oxadiazinan-2-one and (right) (5S,6R)-4-cyclopentyl-5-methyl -6- phenyl-2H-3,4oxadiazinan-2-one.
The temperature was 292K. Shelxl-201236 was used for refinement. The unit cell
parameters were obtained from a least-squares refinement of 8339 unique reflections out
of the 52929 reflections collected. The crystal is monoclinic and crystallizes in the P21
space group. The cell lengths are: a = 10.4323(3) Å, b = 8.7068(2) Å, and
c = 14.6212(4) Å. The volume of the cell is 1324.64(6) Å3 and ρ = 1.240 g/cm3. The
angles of the cell are: α = 90°, β = 94.1200(10)°, and γ = 90°. Z’ is 2 and Z is 2.
Diffraction data were measured between θmin = 1.396° and θmax = 32.151°. The limiting
indices were -15 ≤ h ≤ 15, -12 ≤ k ≤ 12, and -21 ≤ l ≤ 21. All hydrogen atoms attached to
nitrogen were freely refined and all other hydrogens were refined using the riding-model
approximation. Convergence was reached on the full-matrix least-squares refinement on
F2. The R1-factor is 0.0427 and wR2 is 0.1098. An ORTEP33 depiction in Figure 3.6. In
each figure the hydrogen atoms have been omitted for clarity and hydrogen bonds are
shown as dotted lines. In Figure 3.9, the ellipsoids are modeled at 50% probability.
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Figure 3.6 Ellipsoid depiction of 3.

The bond lengths and bond angles of the central oxadiazinanone ring of 3 are
shown in Tables 3.9 and 3.10. In Table 3.11 are found the torsions of the central
oxadiazinanone ring, as well as the carbons attached to the central ring. Table 3.12 shows
the hydrogen bond distances and angles.

Table 3.9 Bond lengths of the central oxadiazinanone atoms of 3.
Atoms-isopropyl
O1-C2
O1-C6
C2-N3
C2-O17
N3-N4
N4-C5
C5-C6

Bond Length (Å)
1.353(2)
1.457(2)
1.342(2)
1.228(2)
1.426(2)
1.474(2)
1.535(2)

Atoms-cyclopentyl
O51-C52
O51-C56
C52-N53
C52-O69
N53-N54
N54-C55
C55-C56
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Bond Length (Å)
1.354(2)
1.458(2)
1.338(2)
1.233(2)
1.424(2)
1.476(2)
1.534(2)

Table 3.10 Bond angles of the central oxadiazinanone rings in the asymmetric unit of 3.
Atoms-isopropyl
C6-O1-C2
O1-C2-N3
O1-C2-O17
O17-C2-N3
C2-N3-N4
N3-N4-C5
C14-N4-C5
N4-C5-C13
C13-C5-C6
C5-C6-O1

Angle (°)
120.2(1)
119.0(1)
117.6(1)
123.4(2)
125.8(1)
107.8(1)
115.5(1)
110.2(1)
113.5(1)
109.1(1)

Atoms-cyclopentyl
C56-O51-C52
O51-C52-N53
O51-C52-O69
O69-C52-N53
C52-N53-N54
N53-N54-C55
C64-N54-C55
N54-C55-C63
C63-C55-C56
C55-C56-O51

Angle (°)
118.6(1)
119.1(1)
117.8(1)
123.1(2)
126.8(1)
108.4(1)
113.7(1)
110.7(1)
113.5(1)
108.6(1)

Table 3.11 Torsion angles of the central rings in the asymmetric unit of 3.
Atoms-isopropyl

Torsion (°)

Atoms-cyclopentyl

Torsion (°)

C6-O1-C2-N3
C6-O1-C2-O17
C2-O1-C6-C5
C2-O1-C6-C7
O1-C2-N3-N4
O17-C2-N3-N4
C2-N3-N4-C5
C2-N3-N4-C14
N3-N4-C5-C6
N3-N4-C5-C13
C14-N4-C5-C6
C14-N4-C5-C13
N4-C5-C6-O1
N4-C5-C6-C7
C13-C5-C6-O1
C13-C5-C6-C7

1.6(2)
-177.9(1)
29.3(2)
155.9(1)
-4.1(2)
175.3(2)
-25.9(2)
101.1(2)
55.1(2)
-70.0(2)
-68.9(2)
166.0(1)
-58.2(2)
-179.4(1)
64.9(2)
-56.3(2)

C56-O51-C52-N53
C56-O51-C52-O69
C52-O51-C56-C55
C52-O51-C56-C57
O51-C52-N53-N54
O69-C52-N53-N54
C52-N53-N54-C55
C52-N53-N54-C64
N53-N54-C55-C56
N53-N54-C55-C63
C64-N54-C55-C56
C64-N54-C55-C63
N54-C55-C56-O51
N54-C55-C56-C57
C63-C55-C56-O51
C63-C55-C56-C57

7.2(2)
-174.6(1)
-38.4(2)
-164.9(1)
2.4(2)
-175.7(1)
21.7(2)
-103.1(2)
-51.6(2)
73.7(2)
71.0(2)
-163.7(1)
61.2(2))
-176.7(1)
-62.4(2)
59.6(2)
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Table 3.12 Donor-Acceptor Hydrogen bond lengths in 3.
DonorAcceptor
O17-N53
N3-O69

Distance, D-A (Å)
2.868
2.895

Bonding Motif
Different
Enantiomorph

Crystallographic Details of Quasiracemate of (5R,6S)-4-Cyclopentyl-5-methyl-6phenyl-2H-1,3,4-oxadiazinan-2-one and (5S,6R)-4-Cyclohexyl-5-methyl6-phenyl-2H-1,3,4-oxadiazinan-2-one, 4
Shelxl-201236 was used for refinement. The crystal dimensions are 0.330 mm x
0.120 mm x 0.100 mm. The temperature was 100K. The unit cell parameters were
obtained from a least-square refinement of 7852 unique reflections out of the 53541
reflections collected. The crystal is monoclinic and crystallizes in the P21 space group.
The cell lengths are: a = 8.8830(3) Å, b = 16.9145(5) Å, and c = 10.0167(3) Å. The
angles of the cell are α = 90°, β = 106.432(2)°, and γ = 90°. The volume of the cell is
1443.55(8) Å3 and ρ = 1.230 g/cm3. Z’ is 2 and Z is 8. Diffraction data were measured
between θmin = 2.120° and θmax = 29.290°. . The limiting indices were -12 ≤ h ≤ 12, -23 ≤
k ≤ 23, and -13 ≤ l ≤ 13. All hydrogen atoms attached to nitrogen were freely refined and
all other hydrogen atoms were refined using the riding-model approximation.
Convergence was reached on the full-matrix least-squares refinement on F2. The R1factor is 0.0455 and wR2 is 0.1126.
ChemDraw30 depictions of the two compounds used to produce 4 are shown in
Figure 3.7.
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Figure 3.7 (5S,6R)-4-Cyclohexyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one (left)
and (5R,6S)-5-methyl-4-cyclopentyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one (right).
An ORTEP 33depiction of 4 can be viewed in Figure 3.8. In each figure the
hydrogen atoms have been omitted for clarity and hydrogen bonds are shown as dotted
lines. The ellipsoids are modeled at 50% probability.

Figure 3.8. Ellipsoid diagram of 4.
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The bond lengths, bond angles and torsions of the central oxadiazinanone ring are
shown in Tables 3.13-3.14. The torsions of the oxadiazinanone ring as well as carbons
attached to the central ring are given in Table 3.11. The hydrogen bond distances and
angles are displayed in Table 3.15.

Table 3.13 Bond lengths in the central oxadiazinanone ring of 4.
Atoms-Cyclohexyl

Bond Length (Å)

Atoms-Cyclopentyl

Bond Length (Å)

O1-C2
O1-C6
C2-N3
C2-O20
N3-N4
N4-C5
C5-C6
C7-C8

1.356(3)
1.442(3)
1.337(3)
1.224(4)
1.422(3)
1.471(4)
1.533(3)
1.391(3)

O51-C52
O51-C56
C52-N53
C52-O69
N53-N54
N54-C55
C55-C56
C57-C58

1.353(3)
1.446(3)
1.343(3)
1.225(4)
1.429(3)
1.476(3)
1.534(3)
1.393(4)

Table 3.14 Bond angles in the central oxadiazinanone rings of 4.
AtomsCyclohexyl
C6-O1-C2
O1-C2-N3
O1-C2-O20
O17-C2-N3
C2-N3-N4
N3-N4-C5
C14-N4-C5
N4-C5-C13

Angle (⁰)

Atoms-Cyclopentyl

Angle (⁰)

118.6(2)
119.1(2)
117.6(2)
123.3(2)
126.8(2)
108.0(2)
116.1(2)
110.0(2)

C56-O51-C52
O51-C52-N53
O51-C52-O69
O69-C52-N53
C52-N53-N54
N53-N54-C55
C64-N54-C55
N54-C55-C63

118.9(2)
118.7(2)
118.3(2)
123.0(2)
126.9(2)
109.2(2)
113.9(2)
110.0(2)
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Table 3.15 Torsion angles of the central oxadiazinanone rings of 4.
Atoms-Cyclohexyl
C6-O1-C2-N3
C6-O1-C2-O20
C2-O1-C6-C5
C2-O1-C6-C7
O1-C2-N3-N4
O20-C2-N3-N4
C2-N3-N4-C5
C2-N3-N4-C14
N3-N4-C5-C6
N3-N4-C5-C13
C14-N4-C5-C6
C14-N4-C5-C13
N4-C5-C6-O1
N4-C5-C6-C7
C13-C5-C6-O1
C13-C5-C6-C7

Torsion (⁰)
-5.1 (3)
177.0(2)
37.8(3)
163.5(2)
-5.5(4)
172.3(2)
-19.6(3)
108.1(3)
51.2(2)
-74.0(2)
-73.0(2)
161.9(2)
-61.8(2)
177.0(2)
61.3(3)
-59.9(3)

Atoms-Cyclopentyl
C56-O51-C52-N53
C56-O51-C52-O69
C52-O51-C56-C55
C52-O51-C56-C57
O51-C52-N53-N54
O69-C52-N53-N54
C52-N53-N54-C55
C52-N53-N54-C64
N53-N54-C55-C56
N53-N54-C55-C63
C64-N54-C55-C56
C64-N54-C55-C63
N54-C55-C56-O51
N54-C55-C56-C57
C63-C55-C56-O51
C63-C55-C56-C57

Torsion (⁰)
7.2(2)
-174.6(1)
-38.4(2)
-164.7(2)
4.1(4)
-173.9(2)
18.3(3)
-107.3(3)
-48.3(2)
76.7(2)
75.0(2)
-160.0(2)
59.9(3))
-178.7(2)
-63.0(3)
58.4(3)

Table 3.16 Donor-Acceptor Hydrogen bond lengths in 4.
DonorAcceptor
N3-O69
O20-N53

Distance, D-A (Å)
2.823
2.859

Bonding Motif
Different
Enantiomorph

Crystallographic Details of 5
In Figure 3.9 is a ChemDraw30 depiction of the product which resulted from the
attempted synthesis of (5R,6S)-4-ethyl-5-methyl-6-phenyl-3H-1,3,4-oxadiazinan-2-one.
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Figure 3.9 Line drawing of 5.

The dimensions of the crystal used for X-ray diffraction were 0.248 mm x 0.201
mm x 0.061 mm. The sample was generally kept at 100 K. Superflip37was used for
solving the structure and Shelxl-201236 was used for refinement. The unit cell parameters
were obtained from a least-squares refinement of 5033 unique reflections out of the
15264 reflections collected. The crystal is orthorhombic and crystallizes in the P212121
space group. The cell lengths are: a = 7.0046(8) Å, b = 10.0479(11) Å, and c = 20.587(2)
Å. The volume of the cell is 1448.94 Å3 and ρ = 1.221 g/cm3. Z’ is 1 and Z is 4.
Diffraction data were measured between θmin = 1.978° and θmax = 28.271°. The limiting
indices were -9 ≤ h ≤ 9, -12 ≤ k ≤ 13, and -27 ≤ l ≤ 27. All hydrogen atoms attached to
nitrogen and oxygen were freely refined and all other hydrogens were refined using the
riding-model approximation. Convergence was reached on the full-matrix least-squares
refinement of F2. The R1-factor is 0.0333 and wR2 is 0.0792. Figure 3.10 shows an
ellipsoid drawing of 5. The ellipsoids are modeled at 50% probability.
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Figure 3.10 Ellipsoid depiction of 5.

The bond lengths, bond angles and torsion angles of the central oxadiazinanone
ring as well as any carbon atoms attached to the ring are shown in Tables 3.17-19. The
hydrogen bond lengths are given in Table 3.20.
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Table 3.17 Bond lengths between atoms in the asymmetric unit of 5.
Atoms

Bond Length (Å)

O1-C2
C2-N3
C2-O17
N3-N4
N4-C5
N4-C15
C5-C6
C5-C14
C6-C7
C6-O13
C7-C8
C7-C12
C8-C9
C9-C10
C10-C11
C11-C12
O13-H13
C15-C16
O17-C18
C18-C19

1.218(2)
1.350(2)
1.349(2)
1.419(2)
1.490(2)
1.479(2)
1.540(2)
1.529(2)
1.518(2)
1.433(2)
1.391(2)
1.399(2)
1.391(3)
1.385(3)
1.383(3)
1.389(3)
0.82(2)
1.517(2)
1.456(2)
1.505(2)
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Table 3.18 Bond angles in 5.
Atoms

Angle (⁰)

O1-C2-N3
O1-C2-O17
N3-C2-O17
C2-N3-N4
N3-N4-C5
N3-N4-C15
C5-N4-C15
N4-C5-C6
N4-C5-C14
C6-C5-C14
C5-C6-C7
C5-C6-O13
C7-C6-O13
N4-C15-C16
C2-O17-C18
O17-C18-C19

126.0(2)
124.9(1)
109.0(1)
118.3(1)
110.1(1)
108.0(1)
112.3(1)
108.4(1)
109.9(1)
111.4(1)
111.5(1)
110.5(1)
110.1(1)
112.1(1)
116.0(1)
110.5(1)
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Table 3.19 Torsion angles in asymmetric unit of 5.
Atoms

Torsion (⁰)

O1-C2-N3-N4
O17-C2-N3-N4
O1-C2--O17-C18
N3-C2-O17-C18
C2-N3-N4-C5
C2-N3-N4-C15
N3-N4-C5-C6
N3-N4-C5-C14
C15-N4-C5-C6
C15-N4-C5-C14
N3-N4-C15-C16
C5-N4-C15-C16
N4-C5-C6-C7
N4-C5-C6-O13
C14-C5-C6-C7
C14-C5-C6-O13
C2-O17-C18-C19

11.3(2)
-171.2(1)
-7.6(2)
174.9(1)
-115.8(2)
121.2(2)
56.6(2)
178.5(1)
177.0(1)
-61.1(2)
-59.0(2)
179.4(1)
179.1(1)
56.3(2)
58.0(2)
-64.7(2)
-80.1(2)

Table 3.20 Donor-Acceptor Hydrogen bond lengths in 5.
Donor-Acceptor

Distance, D-A (Å)

Bonding Motif

N3-O13

2.941

Homoenantiomorph

O1-O13

2.893

Intramolecular

Crystallographic Details of 6
In Figure 3.11 is a ChemDraw30 depiction of the product which resulted from the
attempted synthesis of (5R,6S)-4-n-propyl-5-methyl-6-phenyl-3H-1,3,4-oxadiazinan-2one.

51

O
HN

OH
(S)

(R)

O

N

CH3

Figure 3.11 Line drawing of 6.

The dimensions of the crystal used for X-ray diffraction were 0.339 mm x 0.211
mm x 0.04 mm. The sample was generally kept at 150(2) K. Superflip37 was used for
solving the structure and Shelxl-201236 was used for structure refinement. The unit cell
parameters were obtained from a least-squares refinement of 9971 unique reflections out
of the 37783 reflections collected. The crystal is monoclinic and crystallizes in the P21
space group. The cell lengths are: a = 9.6957(2) Å, b = 15.5239(4) Å, and c = 11.5672(3)
Å. Angle β is 103.4220(10)°. The volume of the cell is 1693.48 Å3 and ρ = 1.155 g/cm3.
Z’ is 2 and Z is 4. Diffraction data were measured between θmin = 2.23° and θmax =
30.26°. The limiting indices were -13 ≤ h ≤ 13, -21 ≤ k ≤ 21, and -15 ≥ l ≤ 15. All
hydrogen atoms attached to nitrogen and oxygen were freely refined and all other
hydrogens were refined using the riding-model approximation. Convergence was reached
on the full-matrix least-squares refinement of F2. The R1-factor is 0.0473 and wR2 is
0.1274 Figure 3.12 shows an ellipsoid drawing of 6. The ellipsoids are modeled at 50%
probability.
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Figure 3.12 Ellipsoid depiction of 6.

The bond lengths, bond angles and torsion angles of the central oxadiazinanone
ring as well as any carbon atoms attached to the ring are shown in Tables 3.21-24. The
hydrogen bond lengths are shown in Table 3.24.
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Table 3.21 Bond lengths between atoms in the asymmetric unit of 6.
Atoms-Molecule 1
O1-C2
C2-N3
C2-O19
N3-N4
N4-C5
N4-C15
C5-C6
C5-C14
C6-C7
C6-O13
C15-C16
C16-C17
C17-18
O19-C20
C20-C21

Length (Å)
1.217(3)
1.343(3)
1.337(3)
1.404(3)
1.484(3)
1.468(3)
1.549(3)
1.517(3)
1.518(3)
1.423(3)
1.530(4)
1.513(4)
1.471(6)
1.442(4)
1.485(4)

Atoms-Molecule 2
O51-C52
C52-N53
C52-O69
N53-N54
N54-C55
N54-C65
C55-C56
C55-C64
C56-C57
C56-O63
C65-C66
C66-C67
C67-C68
O69-C70
C70-C71

Length (Å)
1.215(3)
1.335(3)
1.342(3)
1.418(3)
1.491(3)
1.477(3)
1.540(3)
1.529(4)
1.510(3)
1.423(2)
1.521(3)
1.519(4)
1.514(4)
1.457(5)
1.477(8)

Atoms-Molecule 2
O51-C52-N53
O51-C52-O69
N53-C52-O69
C52-N53-N54
N53-N54-C55
N53-N54-C65
C55-N54-C65
N54-C55-C56
N54-C55-C64
C56-C55-C64
C55-C56-C57
C55-C56-O63
C57-C56-O63
N54-C65-C66
C65-C66-C67
C66-C67-C68
C52-O69-C70
O69-C70-C71

Angle (°)
125.5(2)
123.7(2)
110.7(2)
117.6(2)
110.4(2)
108.0(2)
114.8(2)
108.2(2)
110.1(2)
110.3(2)
111.4(2)
111.6(2)
110.1(2)
111.6(2)
112.4(2)
112.3(3)
115.4(3)
109.0(4)

Table 3.22 Bond angles in 6.
Atoms-Molecule 1
O1-C2-N3
O1-C2-O19
N3-C2-O19
C2-N3-N4
N3-N4-C5
N3-N4-C15
C5-N4-C15
N4-C5-C6
N4-C5-C14
C6-C5-C14
C5-C6-C7
C5-C6-O13
C7-C6-O13
N4-C15-C16
C15-C16-C17
C16-C17-C18
C2-O19-C20
O19-C20-C21

Angle (°)
126.1(2)
124.8(2)
109.1(2)
120.3(2)
112.6(2)
109.2(2)
113.9(2)
114.5(2)
109.7(2)
112.1(2)
111.4(2)
108.1(2)
112.6(2)
110.3(2)
113.3(2)
114.2(4)
115.9(2)
107.1(3)
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Table 3.23 Torsion angles in asymmetric unit of 6
Atoms-Molecule 1
O1-C2-N3-N4
O19-C2-N3-N4
O1-C2-O19-C20
N3-C2-O19-C20
C2-N3-N4-C5
C2-N3-N4-C15
N3-N4-C5-C6
N3-N4-C5-C14
C15-N4-C5-C6
N3-N4-C15-C16
C5-N4-C15-C16
N4-C5-C6-C7
N4-C5-C6-O13
C14-C5-C6-C7
C14-C5-C6-O13
C5-C6-C7-C8
C5-C6-C7-C12
O13-C6-C7-C8
O13-C6-C7-C12
N4-C15-C16-C17
C15-C16-C17-C18
C2-O19-C20-C21

Torsion (°)
1.2(4)
-178.6(2)
0.3(3)
-179.9(2)
-113.7(2)
118.7(2)
-60.3(2)
66.8(2)
64.8(2)
-168.1(2)
-72.3(2)
160.9(2)
-162.4(2)
73.4(2)
71.8(2)
-52.4(2)
-95.5(3)
85.2(3)
26.1(3)
-153.2(2)
171.8(2)
64.8(4)
-179.0(2)

Atoms-Molecule 2
O51-C52-N53-N54
O69-C52-N53-N54
O51-C52-O69-C70
N53-C52-O69-C70
C52-N53-N54-C55
C52-N53-N54-C65
N53-N54-C55-C56
N53-N54-C55-C64
C65-N54-C55-C56
C65-N54-C55-C64
N53-N54-C65-C66
C55-N54-C65-C66
N54-C55-C56-C57
N54-C55-C56-O63
C64-C55-C56-C57
C64-C55-C56-O63
C55-C56-C57-C58
C55-C56-C57-C62
O63-C56-C57-C58
O63-C56-C57-C62
N54-C65-C66-C67
C65-C66-C67-C68
C52-O69-C70-C71

Table 3.24 Donor-Acceptor Hydrogen bond lengths in 6.
Donor-Acceptor

Distance, D-A (Å)

Bonding Motif

O13-N3

2.883

Intramolecular

O13-O51

2.908

Heteroenantiomorph
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Torsion (°)
9.2(3)
-171.6(2)
1.7(4)
-177.6(3)
-115.4(2)
118.4(2)
60.5(2)
-178.9(2)
-177.2(2)
-56.5(2)
-68.9(2)
167.5(2)
-173.7(2)
62.7(2)
65.8(2)
-57.7(2)
69.6(3)
-111.3(2)
-166.0(2)
13.1(3)
175.4(2)
172.3(3)
-159.2(3)

Summary of Crystallographic Details of Crystals Studied in This Research
Tables 3.25 and 3.26 summarize the crystallographic details in this research.

Table 3.25 Summary data for crystallographic details of the oxadiazinanone crystals in
this thesis.
Compound

1

2

3

4

N4 Substituent/type

cyp/pure (5R,6S)

cyp
/racemic

Formula

C15H2-N2O2

C15H20N2O2

C28H38N4O4

C31H42N4O4

Crystal Setting

orthorhombic

monoclinic

monoclinic

Monoclinic

Space Group
Crystal Size
(mm3)

P212121
0.360 x 0.270 x
0.210

P21/c
0.195 x 0.138 x
0.137

P21
0.449 x 0.211 x
0.102

P21
0.330 x 0.120 x
0.100

a (Å)

8.4171(3)

9.1808(3)

10.4323(3)

8.8830(3)

b (Å)

9.0618(4)

15.7560(5)

8.7068(2)

16.915(5)

c (Å)

36.7815(13)

9.7293(3)

14.6212(4)

10.0167(3)

α (°)

90

90

90

90

β (°)

90

106.132(2)

94.1200(10)

106.432(2)

γ (°)

90

90

90

90

VÅ

2805.47

1351.95

1324.64

1443.55(8)

Z; Z'

2; 8

1;4

1;2

2;8

Density

1.233

1.279

1.240

1.230

Temperature

80(2) K

293(2) K

293(2) K

100(2) K

Total # reflections

17571

19297

52929

53541

0.0432

0.0381

0.0427

0.0455

ωR

0.1029

0.0926

0.1098

0.1126

Unique reflections

4581

2460

8339

7852

S

1.160

1.034

1.036

1.019

3

R

1
-factor
2
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(5S,6R)cyp/
(5R,6S)iso

(5S,6R(cyp)/
(5R,6S)iso

Table 3.26 Summary of crystallographic details of crystals studied in this research which
were not oxadiazinanones.
Compound

5

6

Formula

C14H22N2O3

C16H26N2O3

Crystal Setting

orthorhombic

monoclinic

Space Group

P212121

P21

Crystal Size (mm )

0.248 x 0.201 x 0.061

0.339 x 0.211 x 0.04

a (Å)

7.0046(8)

9.6957(2)

b (Å)

10.0479(11)

15.5239(4)

c (Å)

20.587(2)

11.5672(3)

α (°)

90

90

β (°)

90

103.4220(10)

γ (°)

90

90

1448.94

1693.48

1;4

2;4

density g/cm

1.221

1.155

Temperature

100(2) K

150(2) K

Total # reflections

15264

37783

R1-factor

0.0333

0.0473

ωR

0.0792

0.1274

Unique reflections

5033

9971

S

1.038

1.02

3

3

VÅ

Z; Z'
3

2
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CHAPTER IV
DISCUSSION OF CRYSTAL STRUCTURES
In order to better understand the similarities and differences in the oxadiazinanone
compounds studied during this research, it would be helpful to have a summary of some
of the relevant crystallographic details.24, 26, 38 The crystal packing and hydrogen-bonding
motifs will be compared and contrasted in an attempt to understand what causes some
oxadiazinanones to fail to fractionally crystallize and others to succeed. In addition, each
of the new crystal structures found during this research will be discussed.
Summary of the Formation of Quasiracemic Crystals and Some Key
Crystallographic Data Pertaining to the Oxadiazinanones Studied
Tables 4.1-4 summarize the information for each of the enantiomers studied.
Table 4.1 gives the results for each attempt made to isolate a quasiracemic crystal. If a
quasiracemic crystal formed (failure of fractional crystallization), the term “quasi,”
highlighted in blue, can be seen. If a combination was not attempted, the designation N/A
is given. When enantiomers of an oxadiazinanone form a racemic crystal, it is highlighted
in peach. In cases of fractional crystallization, the data show which quasienantiomer was
found (based on the N4 substituent). Tables 4.2-4.3 give crystallographic details for pure
structures, racemic structures and quasiracemic structures of oxadiazinanones,
respectively. In Tables 4.2-4.4 the hydrogen-bonding motif refers to whether the
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hydrogen bonds occur between structures with the same chirality (enantiomorphs) or the
opposite chirality. The bonds between molecules with the same chirality are called homo
enantiomorphic bonds. The bonds between molecules with different chirality are called
hetero enantiomorphic bonds.

Table 4.1 Fractional crystallization results of the combination of (5R,6S)oxadiazinanones
and (5S,6R) oxadiazinanones.
N4 Substituent on (5R,6S) Oxadiazinanone
cyclocyclohexyl
isopropyl
n-propyl
pentyl

N4
Substituent
on (5S,6R)
Oxadiazinanone

methyl

cyclohexyl

racemate2

quasi

quasi2

cyclohexyl

methyl

cyclopentyl

quasi

racemate

quasi

cyclopentyl

methyl

isopropyl

quasi2

N/A3

racemate1

isopropyl

methyl

n-propyl

N/A3

N/A3

N/A3

racemate1

N/A3

methyl

methyl

N/A3

N/A3

N/A3

racemate1

1

Racemates are assumed to form. However the cyclopentyl racemate was the only
racemate attempted in this research.
2
Kate Edler crystallized and reported on these crystals.26
3
N/A indicates the combination was not attempted or crystals were not obtained.

Table 4.2 Crystallographic details of enantiomerically pure compounds.
N4
substituent
cyclohexyl (7)
cyclopentyl (1)

Space
Group
P212121
P212121

Crystal
Setting
orthorhombic
orthorhombic

isopropyl (9)

P212121

n-propyl (13)
methyl (12)

16; 4
8; 2

No. of H-Bonds; Motif
(Asymmetric Unit)
4; homo-enantiomorph
2; homo-enantiomorph

orthorhombic

8; 2

2; homo-enantiomorph

P21

monoclinic

4; 2

4; homo-enantiomorph

P21

monoclinic

2; 1

2; homo-enantiomorph
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Z; Z'

Table 4.3 Crystallographic details of racemic compounds.

isopropyl (11)

Space
Group
C2/c

Crystal
Setting
monoclinic

cyclopentyl (2)

P21/c

cyclohexyl(10)

P-1

N4 substituent

8; 1

No. of H-Bonds; Motif
(Asymmetric Unit)
2; hetero-enantiomorph

monoclinic

4; 1

2; hetero-enantiomorph

triclinic

4; 2

4; hetero-enantiomorph

Z; Z’

Table 4.4 Crystallographic details of quasiracemic compounds.

isopropyl/cyclopentyl (3)

Space
Group
P21

Crystal
Setting
monoclinic

isopropyl/cyclohexyl (8)

P21

cyclohexyl/cyclopentyl (4)

P21

N4 substituents

4; 2

No. of H-Bonds; Motif
(Asymmetric Unit)
4; hetero-enantiomorph

monoclinic

4; 2

4; hetero-enantiomorph

monoclinic

4; 2

4; hetero-enantiomorph

Z; Z’

Most of the oxadiazinanones studied have Z’ > 1. Compound 7 has Z’ of 4. Table
4.5 shows that of the more than 600,000 structures in the Cambridge Structural Database
a Z’ ≤ 1 occurs in about 88% of the crystals. A Z’ of 2 is much less common, and Z’ of 4
is encountered less than 0.4 % of the time.39 These unusually high Z’ values may provide
insight into why some of the compounds form quasiracemic crystals and others do not.
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Table 4.5 The occurrence frequency of structures between Z’ ranges in the Cambridge
Structural Database in 2013.39
Range of Z’ % Structures
0 ≤ Z’ ≤ 1

88.2%

1 < Z’ ≤ 2

10.5%

2 < Z’ ≤ 3

0.6%

3 < Z’ ≤ 4

0.4%

4 < Z’

0.1%

In each quasiracemic crystal the Z’ is less than or equal to the Z’ of the component
quasienantiomers. This is especially notable in the cyclopentyl/cyclohexyl quasiracemate.
The cyclopentyl quasienantiomer, 1, has a Z’ of 2, and the cyclohexyl quasienantiomer, 7,
has a Z’ of 4. After mixing the quasienantiomers together and crystallizing them, the
resulting quasiracemate, 3, has a Z’ of 2. Since this Z’ of 2 includes the two
quasienantiomers, it would be comparable to a Z’ of 1 in a racemate crystal. When the
methyl quasienantiomer is combined with any other quasienantiomer, the methyl always
fractionally crystallizes.
Kitaigorodskii’s close-packing principle states that reduction of volume and
increase in density are major factors in determining the ease with which molecules pack
in the solid state.40 Brock and Dunitz noted that structures with large Z’ values are
associated with packing conflicts. Packing conflicts make it difficult to crystallize some
compounds.34 Although Z’ for 7 is 4, when it co-crystallizes with 1 or 9 the resulting
quasiracemic crystal has Z’ of 2 which is comparable to a Z’ of 1 in a racemate. This may
indicate reduction in packing conflict with the quasiracemate crystal as compared to that
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of either of the pure oxadiazinanone enantiomers making up the racemates.
According to Braun et al., Z’ of 1 is commonly found in racemic crystals, and he
indicated that inversion symmetry is a probable reason.41 In a study by Kelley et al. it was
found that inversion symmetry is very favorable for crystal packing. Inversion symmetry
generally allows the molecules in the crystal to pack in less space, a factor which favors
crystallization according to the close-packing principle.1 Brook et al. observed that the
majority of crystallizations from racemic solutions lead to racemic crystals.42 The most
common space groups, P1, P21/c, C2/c and Pbca, are racemic and these four space
groups account for approximately two-thirds of all organic crystals.42 Even though
quasiracemates do not form true inversion centers, there are pseudo-inversion centers.
The presence of these pseudo-inversion centers may make the quasiracemic crystal more
stable than either of the quasienantiomeric crystals. This would explain why 3, 4, and 8
form quasiracemic crystals. It seems the value of Z’ of the constituents has some impact
on Z’ of the quasiracemic crystal. The pseudo-inversion possible with quasiracemic
crystals also seems to reduce packing conflicts. If packing conflicts can be alleviated by
the formation of a quasiracemic crystal, the quasiracemic crystal is more likely to
crystallize than either of the oxadiazinanone quasienantiomers.
Another observation can be made from the data in Table 4.1. When the isopropyl
derivative and the n-propyl derivative were mixed, the isopropyl derivative crystallized.
When the cyclohexyl and methyl derivatives were mixed, the methyl derivative
crystallized. Finally, when the cyclohexyl and the n-propyl derivatives were mixed, the
cyclohexyl was crystallized. The n-propyl group is more flexible than the isopropyl group
which may help to make it more soluble in the ethyl acetate used for the crystallization
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process. In Figure 4.1, the connecting motif from N4 to the carbon on the N4 substituent
is highlighted in blue. The cyclohexyl and cyclopentyl substituents have a connection
with N4 similar to that of isopropyl, and they crystallize more readily than the
oxadiazinanone with the n-propyl substituent which indicates that they may be more
stable and able to crystallize more easily. In combinations which included a
quasienantiomer with methyl as the N4 substituent, the quasienantiomer with an N4 of
methyl always crystallized first. Methyl is the smallest N4 substituent and will have the
least flexibility possible.

O

O

NH

O

NH

O

NH

O

N

N

N

CH3

O

CH3

CH3

Figure 4.1 Line drawings of 9, 10, and 12.

The principle that says crystallization favors the reduction of packing conflicts
can be observed in the results of the crystallization studies shown in Tables 4.1-4.4.
There seems to be indications that flexibility in a compound’s bonds impacts
crystallization. When 13, the n-propyl derivative, was mixed with a quasienantiomer, 13
appeared to remain in solution. Each time 12, the methyl derivative was mixed with a
quasienantiomer, 12 was the crystal which was isolated. From this it seems that when
methyl is the N4 substituent, it can be crystallized with few packing conflicts. On the
other hand, when n-propyl is the N4 substituent it is less likely to crystallize. This could
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be due to the flexibility in its structure which can create packing conflicts.
It is always important to note that only one crystal from each product was
analyzed by X-ray diffraction. If one determines the existence of a quasiracemic crystal,
the certainty is that the combination of quasienantiomers can form a quasiracemate. In the
case of no quasiracemic crystal being found, one can only say for certain that a
quasiracemate was not found.
Hydrogen bonding remains a significant driving force in the determination of the
shapes of crystal.40 The most acidic hydrogen atoms will bond with the most readily
available hydrogen acceptors. In the case of the oxadiazinanones, the hydrogen bonding
always has the form, R22 (8).14 This means the hydrogen bonds form an eight-member ring

with two hydrogen bond donors and two acceptors. The hydrogen bond occurs between

the carbonyl groups and the amine hydrogens on the molecules in the crystal. According
to the literature,38 the bond lengths between the C3-N3 carbons in oxadiazinanones which
are unsubstituted at the N3 position (the case for all the oxadiazinanones studied in this
research) is shorter than those which are substituted. The C3-N3 bond lengths in
oxadiazinanones unsubstituted at N3 are in the range 1.389-1.418Å. Two structures
substituted at N3 have C3-N3 bond lengths of 1.337(2) Å and 1.342(2) Å.39 This
indicates the presence of greater double bond character for this bond. This double bond
character could play a role in the strong preference these compounds have for hydrogenbonding. It is worth noting that hydrogen bonding can occur between the same
enantiomorphs, referred to as a homo-enantiomorph motif, or different ones, a heteroenantiomorph motif. Tables 4.2-4.4 indicate the bonding motif for each crystal studied.
Another driving force for a particular type of crystal packing is the minimization
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of electrostatic energy. Although this is very important in ionic crystals, it also is true in
molecular crystals.40 The localized charges on the atoms are small, but remain important
in the packing of the crystals. Minimizing these forces happens when positive and
negative charges are optimized. As described by Brock, this is much like having bumps
against hollows, donors against acceptors, positive ends of dipoles against negative
ends.40 This helps to increase density and minimize volume, implying reduced packing
conflicts. Hydrogen-bonding which is prevalent in oxadiazinanone crystals can help to
minimize electrostatic energy.
Springuel et al. summarized the formation of co-crystals by concluding that the
formation of co-crystals is a summation of molecular geometry, steric hindrance and
hydrogen-bonding.43 This appears to be the case in the structures of this thesis.
Analysis of (5R,6S)-4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan-2-one, 1
Compound 1 packs in space group P212121. This non-centrosymmetric group has
three screw axes orthogonal to each other with no other symmetry elements. Because
there is no other symmetry, the two molecules are not crystallographically identical. This
could be due to conformational differences in the two molecules or flexibility in the
hydrogen-bonding.44 There are two molecules in the asymmetric unit. The packing
diagram is shown in Figure 4.2.
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Figure 4.2 Packing diagram of 1.

The data from an X-ray diffractometer must be converted to a set of coordinates
which describe the crystal in three-dimensional space. Once this data has been obtained,
Mercury a software package developed by the Cambridge Crystallographic Data Centre,
can create images of the crystals. This data can be used to analyze crystal structures
including bond distances, torsion angles, hydrogen bonding and symmetry. One reason
for having more than one molecule in the asymmetric unit of a crystal is that the
molecules have different conformations.41 To determine whether this is the case for 1, an
overlay was done using Mercury.45 In Figure 4.3 is a wireframe depiction of 1. The three
atoms in the central oxadiazinanone ring marked in yellow were chosen as the atoms over
which a least squares fit was calculated.
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Figure 4.3 Overlay of the two molecules in the asymmetric unit of 1.

When an overlay is calculated in Mercury,45 the closest fit will be found in the
atoms chosen for the least squares calculation, and the farther from these atoms one goes,
the greater the differences will appear. Figure 4.3 shows that these two molecules differ
the most in their structure where the cyclopentyl group is located. This could be the
source of the unexpected asymmetry. Even when the overlay is calculated using atoms in
the cyclopentyl substituent, there is still a difference in the conformation of the
cyclopentyl group.
When two molecules are present in the asymmetric unit of pure enantiomers,
hydrogen bonding can allow some flexing of the bonds. This creates some slight
differences in the two molecules. This flexing creates a situation which distorts the
inversion centers.1
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Analysis of the Racemate of 4-Cyclopentyl-5-methyl-6-phenyl-2H-1,3,4-oxadiazinan2-one, 2
Compound 2 crystallizes in the non-chiral, centrosymmetric space group P21/c,
the most common space group. This space group comprises over one-third of the crystals
in the Cambridge Structural Database.46 Because the crystal is a racemate it does not have
optical activity. Although two different enantiomers are present in the structure, there is
only one molecule in the asymmetric unit (Z’ = 1) because the enantiomers, by definition,
are mirror images of each other. That means that if there is one enantiomer present, the
other can be obtained by a symmetry operation (inversion). The unit cell has two glide
planes, two 2-fold screw axes and an inversion center. The packing diagram in Figure
4.4 shows the 4 structures in the unit cell.

Figure 4.4 Packing diagram of 2.

In the racemate, 2, hydrogen-bonding is observed between different
enantiomorphs in the crystal. This differs from the bonding that occurs in 11 (see Table
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4.3) where the hydrogen bonding occurs between the same enantiomorphs even though it
is also a racemic crystal.
Analysis of the Quasiracemate of (5R,6S)-5-Methyl-4-cyclopentyl-6-phenyl-2H-1,3,4oxadiazinan-2-one and (5S,6R)-4-Isopropyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one, 3
Compound 3 packs in the non-centrosymmetric space group P21 and has one
symmetry element, a screw axis. The hydrogen-bonding motif is hetero-enantiomorphic.
There are 2 molecules in the asymmetric unit (see Figures 3.9 and 10). The packing
diagram can be seen in Figure 4.5.

Figure 4.5 Packing diagram of 3.
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This quasiracemate compares to 8 (see Table 4.4) in that they both crystallize in
the space group P21. Both have two molecules in the asymmetric unit—one
oxadiazinanone with an N4 cyclohexyl substituent and the other with an N4 substituent of
isopropyl or cyclopentyl. This compound could possibly be modeled as a
centrosymmetric crystal with disorder in the area of the isopropyl and cyclopentyl
substituents with half occupancy of each of the substituents. Figure 4.6 shows an overlay
of the quasienantiomers. The hydrogen atoms have been omitted for clarity.

Figure 4.6 Overlay of 2 and 3.

In this overlay the nitrogen atoms and oxygen atoms used in the hydrogenbonding have been used to determine the least squares alignment of the structures. It is
important to note that as one looks further from the center where the structures are
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aligned, the differences become more exaggerated. In this overlay it seems that the
isopropyl substituent and the cyclopentyl constituent are closely aligned and that this
could be solved in a centrosymmetric space group.
In Figure 4.7 one can compare the hydrogen-bonded dimers of 2 and 3. The
similarities are striking—again making a case for the possibility of solving the structure
in a centrosymmetric space group. The hydrogen atoms have been omitted for clarity.

Figure 4.7 The hydrogen-bonded dimers of 2 (top) and 3 (bottom).
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Compound 2 has an inversion center located within the hydrogen bonds and, of
course 3, does not. However, Compound 3 could have a pseudo-inversion center located
within the hydrogen bonds. Figure 4.8 shows 2 and 3 from an angle which allows one to
compare the hydrogen bonds. Again, hydrogen atoms have been omitted for clarity.

Figure 4.8 The upper structure is a wireframe depiction of the quasiracemate, 3, and the
lower structure is that of the racemate, 1. Both structures are shown from a perspective
parallel to the hydrogen-bonds.

In Figure 4.8 one can see that the hydrogen bonds in 1 appear parallel to each
other and the molecule does not show much flexion in the bonds. In 3, the hydrogen
bonds are skewed in slightly different directions, and there is some flexing of the
different enantiomers. This is further evidenced in the difference in the torsion angles
between the four atoms which are hydrogen bonded. In 1 the torsion angle is 0.00(5)° and
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in 3 the torsion angle is 3.86(6)°. The distances between the nitrogen and oxygen atoms
in the hydrogen bonds in 3 are 2.868(2) Å and 2.895(2) Å. The distance between the
nitrogen and oxygen atoms in the hydrogen bonds in 2 is 2.824(2) Å. It can be seen,
therefore, that there is more discrepancy between the structures than is immediately
evident.
Analysis of the Quasiracemate of (5R,6S)-5-Methyl-4-cyclopentyl-6-phenyl-2H-1,3,4oxadiazinan-2-one and (5S,6R)-4-Cylohexyl-5-methyl-6-phenyl-2H-1,3,4oxadiazinan-2-one, 4
Compound 4 crystallizes in the monoclinic, chiral P21 space group. There are two
molecules in the asymmetric unit (see Figure 3.11). The only symmetry element present
is a two-fold screw axis. As in 2, hydrogen bonding in 4 occurs between the two
quasienantiomers in a hetero-enantiomorph motif. In Figure 4.9 one can see the packing
of 4 in the unit cell. Hydrogen atoms have been omitted for clarity.

Figure 4.9 Packing diagram of the unit cell of 4.
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In Figure 4.10 one can see the overlay of 2 (racemate) and 4 (quasiracemate). In
this overlay the nitrogen atoms and oxygen atoms at each of the double bonds have been
used in the least squares analysis. These atoms near the center of the structure are forced
to be aligned as closely as possible which cause the differences to be exaggerated as one
analyzes the differences further from the center. With that concept in mind, one can see
the close alignment of the cyclopentyl group in the racemate and the cyclohexyl group in
the quasiracemate.

Figure 4.10 Overlay of 2 and 4.

In Figure 4.11 one can see that the hydrogen bonds in 2 and 4 are very similar and 4
seems to have little flexion. In 1 the torsion angle is 0.00(5)° and in 3 the torsion angle is
0.52(9)°. The distances between the nitrogen and oxygen atoms in 4 are 2.859(3) Å and
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2.823(3) Å. The distance between the nitrogen and oxygen atoms in each of the hydrogen
bonds in the racemate 2 is 8.824(2) Å.

Figure 4.11 Hydrogen-bond comparison of 2 (top) and 4 (bottom).
The comparison of the hydrogen bond angles and torsion angles between 2 and 4
are closer than those between 2 and 3 as can be seen in Table 4.6.

Table 4.6 Torsion angles and bond distances in the hydrogen bond motifs of 2, 3 and 4.
Hydrogen Bond Distances
(Å)
Donor to Acceptor

Atoms

Torsion Angles
(°)

Compound 2 2.824(2) Å

N3-O19-N3-19

0.00(5)

Compound 3 2.868(2) Å; 2.895(2) Å

O69-N3-O17-N53

3.86(6)

Compound 4 2.859(3) Å; 2.823(3) Å

O69-N5-O20-N53

0.52(9)
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The similarity in the structure for racemic cyp and cyp/cyh leads one to wonder if
the quasiracemate could be solved in a centrosymmetric space group modeling a disorder
with the cyclohexyl quasiracemate and the cyclopentyl racemate present in equal
amounts. This modelling was attempted and Figure 4.12 shows the resulting asymmetric
unit.

Figure 4.12 Asymmetric unit of 4 solved in P21/c space group.
In this structure the lengths of the hydrogen bonds are both 2.77(1) Å. The torsion
angles are 0.0°. These values are constrained because the second molecule is generated
by an inversion. The extra atoms that can be seen around the N4 substituent represent the
disorder at the N4 substituent. When solved in the centrosymmetric space group P21/c, Z
= 4 and Z’ = 1. The R1-factor is 0.1635 and wR2 is 0.3397. The R-factors are higher than
what should be accepted in a structure, but it is conceivable that they are low enough that
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this could be used as a proof of concept. The definition of a quasiracemate could be
changed to reflect the ability of the structure to be solved in a centrosymmetric space
group with some higher level of R-values, weighted or un-weighted. This definition does
not mean the structure should be solved and published as a centrosymmetric crystal, but
that the structure is capable of being solved in a centrosymmetric space group. This also
indicates that the Z‘ = 2 of 4 is a bit misleading, because it is much like 2 which has a Z’
of 1.
Analysis of 5
Compound 5 (Figure 3.13) was the result of an attempt to synthesize an
oxadiazinanone substituted at the N4 position with an ethyl group. The cyclization
reaction, after purification with flash chromatography, appeared to produce the desired
product based on the 1H NMR spectrum.
After solving the structure using X-ray diffraction, it was found that the N4
substituent was the ethyl group but the ring had not closed. It is possible that the desired
product was produced in addition to the product which was identified by X-ray
diffraction, but the oxadiazinanone was more soluble than the non-cyclized product and
did not crystallize. Figure 4.13 gives the reaction for the synthesis of the non-cyclized
product, (1S,2R) 2-[N-ethyl-N’-o-ethyl hydrazinoate]-1-phenyl-propan-2-ol, 5, from the
hydrazine of the ethyl derivative of (1S,2R) norephedrine.

77

O
NH2

OH
(S)

(R)

N

CH3

HN

OH
LiH, diethyl carbonate

(S)

O

N
(R)

Dry hexanes

CH3

Figure 4.13 An attempt to cyclize the hydrazine of the ethyl derivative of (1S,2R)
norephedrine resulted in 5.

Compound 5 crystallizes in the orthorhombic space group, P212121, and has one
molecule in the asymmetric unit (Z’ = 1). The compound has three 2-fold screw axes as
the only elements of symmetry. The asymmetric unit has two hydrogen bonds. Figure
3.14 shows that one of the hydrogen bonds is homoenantiomophic and one is an
intramolecular bond. It is interesting to note that the hydroxyl group at O13 is a proton
donor to the intramolecular carbonyl group and a proton acceptor from the secondary
amine at N3. In Figure 4.14, it can be seen that there are four molecules in the unit cell,
therefore Z = 4.

Figure 4.14 Packing diagram of the unit cell of 5.
78

Analysis of 6
Compound 6 (Figure 3.14) was the result of an attempt to synthesize an
oxadiazinanone substituted at the N4 position with an n-butyl group. The cyclization
reaction, after purification with flash chromatography, appeared to produce the desired
product based on the 1H NMR spectrum.
After solving the structure using X-ray diffraction, it was found that the N4
substituent was the n-butyl group but the ring had not closed. It could be that the desired
product was produced in addition to the product which was identified by X-ray
diffraction, but the oxadiazinanone was more soluble than the non-cyclized product and
did not crystallize. Figure 4.15 gives the reaction for the synthesis of the non-cyclized
product, (1S,2R) 2-[N-n-butyl-N’-o-n-butyl hydrazinoate]-1-phenyl-propan-2-ol, 6, from
the hydrazine of the n-butyl derivative of (1S,2R) norephedrine.
.
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Figure 4.15 An attempt to cyclize the hydrazine of the n-butyl derivative of (1S,2R)
norephedrine resulted in synthesis of 6.

The compound crystallizes in the monoclinic space group, P21, and has two
molecules in the asymmetric unit (Z’ = 2). The only symmetry element is a two-fold
screw axis. This compound has only two hydrogen bonds. One of the bonds is
intramolecular. The other is between a carbonyl group and an alcohol group on the other
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molecule in the asymmetric unit. Using symbols and terminology of Etter et al.,14 this
would have two motifs, S(6) and D, indicating the intramolecular bond (S) and the bond
between the two molecules of the asymmetric unit (D).
Figure 4.16 shows the packing diagram of the unit cell. The two molecules,
although the same compound, have different conformations. This is readily apparent
when the two molecules are compared in Tables 3.22 and 3.23. The n-butyl group has
enough flexion in the bonds and angles that perhaps the conformation changes enable the
molecules to pack more densely.

Figure 4.16 Packing diagram of the unit cell of 6.

Polymorphic transformation was displayed in 6. When the temperature of data
collection of the n-butyl derivative was 150 K, the crystal was monoclinic and when the
temperature was lowered to 100 K, the crystal morphed to a triclinic crystal.
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Crystallographic details could not be determined as the crystal shattered as it was cooled
down. Polymorphic transformation can occur as the sizes of the atoms making up the
compound increase or decrease based on the temperature. As the vibrations in the atom
increase with increasing temperature, the increasing size of the molecule may make a less
compact crystal more stable.47 The incidence of polymorphism is common if this
statement of Walter C. McCrone is true: “Every compound has different polymorphic
forms, and that, in general, the number of forms known for a given compound is
proportional to the time and money spent in research on that compound.”48,49
In each of 5 and 6, the diethyl carbonate attached as expected to the amine group,
but failed to attach at the hydroxyl group. The hydroxyl group has a stronger bond than
the ammonia group, so the ammonia group left first and allowed the attachment of the
diethyl carbonate. Changing the experimental procedure could produce the desired
oxadiazinanone in each case. If the hexanes used as the solvent are not completely dry,
the LiH will react with water more readily than with the hydrazine. Therefore, every
effort must be made to ensure that the hexanes are dry. If the fourth step of the synthesis
is repeated with the uncyclized product, the desired oxadiazinanone should be obtained.
The LiH:hydrazine mole ratio was 1:2. Perhaps a greater concentration of LiH would also
be effective in producing the oxadiazinanone.
General Conclusions and Future Work
At this point in the study of quasiracemates, the need is to acquire a database of
structures. From this database it is hoped that the reasons for the formation of
quasiracemic crystals with some compounds and not others can be elucidated. The
knowledge gained from the study has the potential to direct the engineering of crystals to
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meet specific needs. To that end, this research can be helpful. The more data collected,
the more knowledge may be gained about the reasons for quasiracemate cocrystallization.
The research goals for this project were met. The inventory of oxadiazinanones
was increased. A new oxadiazinanone, (5R,6S)-4-cyclopentyl-5-methyl-6-phenyl-2H1,3,4-oxadiazinan-2-one, was synthesized. Attempts to combine oxadiazinanone
enantiomers to form quasiracemates were made and two new quasiracemates were
formed. Hydrogen bonding and the number of structures in the asymmetric unit were
investigated as they related to the formation of the quasiracemates. The structure
similarities of those quasienantiomers involved in quasiracemate formation were
compared and an isopropyl type of connection to N4 seemed to be a common bond.
How similar must the quasienantiomers be to co-crystallize? Further research
with oxadiazinanones with different N4 substituents would be useful in determining this.
Will oxadiazinanones form quasiracemates with oxadiazinathiones? Will the
crystallization of oxadiazinathiones quasiracemates mirror that of oxadiazinanone
compounds? The synthesis of oxadiazinanthiones with varying N4substiuents and the
subsequent combination of them with other oxadiazinanthiones or oxadiazinanones will
provide new data. This data will perhaps provide new answers and probably raise some
more questions.
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